Roiver Score™ for
TCRXTScan Therapeutics, Inc. Common Stock
Biological Products, (No Diagnostic Substances)
Based on fundamentals through 12/31/2025.
As of December 31, 2025, TScan Therapeutics, Inc. Common Stock (TCRX) scores 20/100 (Weak) on the Roiver Score — a transparent quality composite. Its strongest area is capital structure; its weakest is stability. The score measures business quality, not timing — it's a signal, not a recommendation.
No black box
Roiver Score is a transparent 0–100 quality composite. Five components, each 0–20: profitability, capital structure, cash quality, valuation, and stability. Inspired by Piotroski's F-Score, Altman's Z-Score, and the Buffett/Munger framework on quality compounders at fair prices. Read the full methodology →
Frequently asked about TCRX
What is TCRX's Roiver Score?
TScan Therapeutics, Inc. Common Stock scores 20 out of 100 (Weak) as of December 31, 2025, based on fundamentals.
How is the Roiver Score for TCRX calculated?
It sums five 0–20 components — profitability, capital structure, cash quality, valuation, and stability — into a transparent 0–100 composite. The full methodology is published.
Is TCRX a good quality stock?
On quality, TCRX rates "Weak" (20/100). Its strongest driver is capital structure and its weakest is stability. Quality is one input to a decision, not a buy/sell call.
Embed on your site
Drop this iframe into a Substack, blog post, or notion page. Updates automatically as fundamentals change.
<iframe src="https://roiver.com/embed/score/TCRX" width="640" height="280" frameborder="0" style="border:0;border-radius:16px;overflow:hidden" loading="lazy"></iframe>
Get TCRX's Score in your inbox
A free weekly digest of quality scores and what changed. No account needed.
Educational use only. Roiver Score is a quality signal, not a recommendation.